Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

EPIC Fail For Mast Therapeutics’ Lead Drug Sends Shares Into Freefall

Executive Summary

Shares in Mast Therapeutics dropped by more than 80% upon news that a Phase III trial of its lead product vepoloxamer in sickle cell disease had failed.


Related Content

Deal Watch: J.P. Morgan Brings Continued Brisk Pace Of Transactions
Novartis Buys Selexys As Competitors Stumble In Sickle Cell
Modus's Intended IPO to Spur Sickle Cell Drug R&D
Emmaus Sickle Cell NDA Facing FDA Concerns About Clinical Meaningfulness
Mast Accelerates Enrollment In Pivotal Sickle Cell Study Of MST-188
Mast Therapeutics Changes Its Name In Hopes Of A Fresh Start


Related Companies